Meningitis drug hope
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Hopes of finding a way to stem meningitis child deaths were raised yesterday by results from the first patient trial of a new drug. Despite treatment with antibiotics, between 20-50 per cent of children who contract the blood infection meningococcal septicaemia die, usually within 24 hours. Those who survive are often left disabled from brain injury or suffer gangrene leading to the loss of limbs.
The new drug, a genetically engineered version of a protein produced by human immune cells to combat infection, dramatically cut the expected number of deaths in a small group of seriously ill children. Researchers at the University of Texas in the United States said the results were far better than expected for such ill patients.
l A 20-year-old engineering student at the University of Sussex in Brighton is believed to have died from meningococcal meningitis. He is the second student to die of the disease in days. Earlier this week a first-year student at Portsmouth University died.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments